MISSISSAUGA, Ontario – (COMMERCIAL THREAD) –MedX Health Company (“MedX” or the “Company”) (TSX-V: MDX) a world leader in teledermatology, is pleased to announce a distribution agreement with VidaCeuticals Health Products Inc. which will see MedX’s integrated skin assessment teledermatology platform offered in four clinics in Ontario starting in late June, with plans for wider deployment on the market in Canada and the United States later this year. The first four clinics will be located in London, Ottawa, Port Elgin and Sarnia.
“With only about 500 dermatologists available to serve over 37 million Canadians, wait times to see a dermatologist in person can range from five months to a year,” said Sylvain Desjeans, chief revenue officer of MedX. “The COVID-19 pandemic has almost doubled the average waiting period. We know that early detection of melanoma dramatically increases patient survival rates and lowers costs to the healthcare system. Increasing accessibility to digitization through a partnership with VidaCeuticals and its extensive network of clinical partners will help us work on the early detection of skin cancer.
Alignment with company values and a passion for saving lives prompted VidaCeuticals Health Products Inc. to connect with MedX to support a strategic and aggressive distribution plan to reach more North Americans with the technology of MedX – its SIAscope ™ imaging device and DermSecure ™ cloud-based telemedicine platform.
“We share values and a passion for finding solutions that are easy to access and which ultimately improve and save lives, avoiding unnecessary impacts on the health of families and communities,” explained Jean- Guy Bourguignon, Managing Director of VidaCeuticals Health Products Inc. “VidaCeuticals looks forward to growing with MedX to expand into Canada and the United States with a mission to increase access to skin screening and lesion assessment, thus improving patient outcomes.
According to the Canadian Dermatology Association, last year approximately 8,000 Canadians were diagnosed with melanoma of the skin and approximately 1,300 Canadians died from it. With death rates increasing by up to 1.2% per year since 1984, early and rapid detection is essential to improve patient outcomes.
MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin health with its SIAscopy ™ telemedicine platform on DermSecure ™, using its SIAscopy ™ technology . SIAscopy ™ is also integrated into its SIAMETRICS ™ products, a renowned research system used to evaluate the effectiveness of treatment of various skin conditions, including burns. The SIAscope ™ and other company devices are manufactured in its ISO 13485 certified facility. The SIAscope ™ is a hand-held device that uses patented technology using light and its transfer to visualize up to 2mm below moles. and suspicious lesions in a painless and non-invasive way, with its software then creating real-time images for doctors and dermatologists to assess all types of moles or lesions in seconds. These products are approved by Health Canada, FDA, TGA, and CE for use in Canada, United States, Australia, New Zealand, European Union, Turkey, and Brazil. DermSecure ™ meets all relevant privacy, security and regulatory requirements in Canada, US, Brazil and EU. MedX also designs, manufactures and distributes quality therapeutic and dental photobiomodulation lasers to provide drug-free, non-invasive treatment for tissue damage and pain. www.medxhealth.com
About VidaCeuticals Health Products
VidaCeuticals Health Products Inc. focuses on connecting people with innovative health solutions, with an emphasis on distributing exclusive and innovative product lines and devices, helping people achieve longevity through a healthier quality of life too naturally as possible. Visit: www.VidaCeuticals.com
This press release does not constitute an offer to sell any securities. This press release contains certain forward-looking statements within the meaning of applicable Canadian securities laws. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ, including, without limitation, the Company’s limited operating history and loss history, failure to achieve successful additional financing, inability to raise capital on terms acceptable to the business, inability to compete effectively in the market, inability to complete the proposed acquisition and other risks that could result in so that actual results differ materially from those contained in the company’s projections or forward-looking statements. All forward-looking statements contained in this press release are based on information available to the company as of the date hereof, and the company does not undertake to update any forward-looking statements to reflect events or circumstances occurring after the release. date of this press release.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.